



RECEIVED

JAN 28 2003

1644

TECH CENTER 1600/2900

PATENT

Attorney Docket No. P04854US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

P#10

APPLICANT: Campbell et al. Group Art Unit: 1644
SERIAL NO: 09/973,284 Examiner: Haddad, M.
FILED: October 9, 2001 Confirmation No: 5785
TITLE: METHODS AND COMPOSITIONS FOR TREATMENT OF IMMUNE DYSFUNCTION DISORDERS

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BEFORE MAILING DATE OF EITHER A FINAL
OFFICE ACTION OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This information disclosure statement is being filed *before* the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311, whichever occurs first.

Attached are Forms PTO/SB/08A and 08B (formerly Form PTO-1449) listing the relevant art known to the applicant herein. Copies of the listed references are enclosed. The Examiner is requested to consider the references and make them of record.

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose. Legible copies of all items listed in Forms PTO/SB/08A and 08B (formerly Form PTO-1449) accompany this information statement.

Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

CERTIFICATE OF MAILING

I hereby certify that the above correspondence was mailed to the Assistant Commissioner for Patents, Washington, D.C. 20231, as First Class mail, postage prepaid, this 21 day of January, 2003.


Heidi S. Nebel

Authorization is hereby made to charge any additional fees required by this paper or credit any overpayment to Deposit Account 26-0084. A duplicate of this paper is attached.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. (Notice of January 9, 1992, 1135 O.G. 13-25, at 25.)

Respectfully submitted,



Heidi S. Nebel, Reg. No. 37,719
McKEE, VOORHEES & SEASE, P.L.C.
801 Grand Avenue, Suite 3200
Des Moines, Iowa 50309-2721
Phone No. (515) 288-3667
Fax No. (515) 288-1338
CUSTOMER NO: 22885

- kpa -

Attorneys of Record



PATENT
Attorney Docket No. P04854US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Campbell et al.
SERIAL NO: 09/973,284
FILED: October 9, 2001

Group Art Unit: 1644
Examiner: Haddad, M.
Confirmation No: 5785

RECEIVED
METHODS AND COMPOSITIONS FOR TREATMENT OF IMMUNE
DYSFUNCTION DISORDERS

JAN 28 2003

TECH CENTER 1600/2900 THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BEFORE MAILING DATE OF EITHER A FINAL
OFFICE ACTION OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This information disclosure statement is being filed *before* the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311, whichever occurs first.

Attached are Forms PTO/SB/08A and 08B (formerly Form PTO-1449) listing the relevant art known to the applicant herein. Copies of the listed references are enclosed. The Examiner is requested to consider the references and make them of record.

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose. Legible copies of all items listed in Forms PTO/SB/08A and 08B (formerly Form PTO-1449) accompany this information statement.

Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

CERTIFICATE OF MAILING

I hereby certify that the above correspondence was mailed to the Assistant Commissioner for Patents, Washington, D.C. 20231, as First Class mail, postage prepaid, this 21 day of January, 2003.


Heidi S. Nebel

Authorization is hereby made to charge any additional fees required by this paper or credit any overpayment to Deposit Account 26-0084. A duplicate of this paper is attached.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. (Notice of January 9, 1992, 1135 O.G. 13-25, at 25.)

Respectfully submitted,



Heidi S. Nebel, Reg. No. 67,719
McKEE, VOORHEES & SEASE, P.L.C.
801 Grand Avenue, Suite 3200
Des Moines, Iowa 50309-2721
Phone No. (515) 288-3667
Fax No. (515) 288-1338
CUSTOMER NO: 22885

- kpa -

Attorneys of Record